FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Brookfield Medical Cited on Repeated Potency Failures

[ Price : $8.95]

FDA cites Connecticut outsourcing facility Brookfield Medical/Surgical Supplies for inadequate investigations involving 13 out-of-...

FDA EDDO Control Strategy Guidance Analyzed

[ Price : $8.95]

Staff from FDA and several drug companies use a Journal of Regulatory Affairs article to explain a 2024 FDA guidance on optimizing...

FDAs OCP Maps Out AI, Modeling and Evidence Priorities

[ Price : $8.95]

A new report by CDERs Office of Clinical Pharmacology says regulatory science will have to evolve alongside increasingly complex t...

User Fee Agreement Opens New Tools to Head Off CRLs: Analysis

[ Price : $8.95]

FDAs proposed drug user fee commitments could give drug and biologics sponsors several new opportunities to address manufacturing ...

Final Year of CMC Development Pilot Opens Oct. 1

[ Price : $8.95]

FDA begins next month accepting requests from drug and biologics sponsors seeking to participate in the fifth and final year of it...

Senate Drug Manufacturing Transparency Bill Watered Down

[ Price : $8.95]

A bipartisan Senate bill intended to give patients and health care providers more information about where prescription drugs are m...

Kennedy Vaccine Remarks Raise Stakes for Overton Confirmation Hearing

[ Price : $8.95]

HHS secretary Robert F. Kennedy Jr.'s vaccine skepticism remarks this week likely complicate Heidi Overtons upcoming confirmation ...

FDA Approves Lilly Combo for Metastatic Breast Cancer

[ Price : $8.95]

FDA grants Eli Lilly full approval for the combination use of Inluriyo (imlunestrant) with Verzenio (abemaciclib) in certain adult...

20 State AGs Warn About Chinese API Suppliers for GLP-1s

[ Price : $8.95]

A coalition of 20 state attorneys general urge the Trump administration to tighten or suspend an FDA import program, alleging that...

Interchangeable Product Development Strategy Outlined

[ Price : $8.95]

FDA issues a strategy document summarizing discussions at a 2025 workshop on developing interchangeable biosimilar products.